Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.12
MDT's Cash to Debt is ranked higher than
56% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. MDT: 1.12 )
MDT' s 10-Year Cash to Debt Range
Min: 0.15   Max: 9.58
Current: 1.12

0.15
9.58
Equity to Asset 0.52
MDT's Equity to Asset is ranked higher than
55% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. MDT: 0.52 )
MDT' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.82
Current: 0.52

0.48
0.82
Interest Coverage 28.15
MDT's Interest Coverage is ranked higher than
59% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. MDT: 28.15 )
MDT' s 10-Year Interest Coverage Range
Min: 6.58   Max: 352.69
Current: 28.15

6.58
352.69
F-Score: 5
Z-Score: 4.04
M-Score: -2.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 25.62
MDT's Operating margin (%) is ranked higher than
96% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 6.75 vs. MDT: 25.62 )
MDT' s 10-Year Operating margin (%) Range
Min: 16.71   Max: 66.79
Current: 25.62

16.71
66.79
Net-margin (%) 20.90
MDT's Net-margin (%) is ranked higher than
94% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.06 vs. MDT: 20.90 )
MDT' s 10-Year Net-margin (%) Range
Min: 11.03   Max: 22.78
Current: 20.9

11.03
22.78
ROE (%) 18.57
MDT's ROE (%) is ranked higher than
95% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. MDT: 18.57 )
MDT' s 10-Year ROE (%) Range
Min: 12.38   Max: 33.4
Current: 18.57

12.38
33.4
ROA (%) 9.95
MDT's ROA (%) is ranked higher than
89% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. MDT: 9.95 )
MDT' s 10-Year ROA (%) Range
Min: 8.78   Max: 24.21
Current: 9.95

8.78
24.21
ROC (Joel Greenblatt) (%) 68.22
MDT's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 12.75 vs. MDT: 68.22 )
MDT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 44.94   Max: 136.71
Current: 68.22

44.94
136.71
Revenue Growth (%) 4.20
MDT's Revenue Growth (%) is ranked higher than
69% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. MDT: 4.20 )
MDT' s 10-Year Revenue Growth (%) Range
Min: 4.2   Max: 17.9
Current: 4.2

4.2
17.9
EBITDA Growth (%) 3.10
MDT's EBITDA Growth (%) is ranked higher than
79% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. MDT: 3.10 )
MDT' s 10-Year EBITDA Growth (%) Range
Min: -15.5   Max: 45.4
Current: 3.1

-15.5
45.4
EPS Growth (%) 6.50
MDT's EPS Growth (%) is ranked higher than
79% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. MDT: 6.50 )
MDT' s 10-Year EPS Growth (%) Range
Min: -4.7   Max: 27.1
Current: 6.5

-4.7
27.1
» MDT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

MDT Guru Trades in Q2 2013

John Buckingham 16,237 sh (New)
Jim Simons 37,100 sh (New)
Steven Cohen 77,188 sh (+479.71%)
Jeremy Grantham 9,643,318 sh (+14.42%)
Pioneer Investments 357,759 sh (+8.54%)
Bill Nygren 4,385,000 sh (+4.78%)
James Barrow 32,245,022 sh (+4.65%)
Scott Black 21,304 sh (+1.96%)
Bill Frels 4,183,307 sh (+0.43%)
Chris Davis 352,932 sh (+0.34%)
Jean-Marie Eveillard 8,000 sh (unchged)
Tom Russo Sold Out
Jeff Auxier 153,770 sh (-0.65%)
Dodge & Cox 9,853,693 sh (-0.83%)
PRIMECAP Management 32,130,321 sh (-0.94%)
HOTCHKIS & WILEY 1,758,047 sh (-1.65%)
John Keeley 48,250 sh (-1.67%)
Vanguard Health Care Fund 10,532,800 sh (-2.48%)
Chuck Royce 91,900 sh (-4.27%)
Manning & Napier Advisors, Inc 355,509 sh (-9.52%)
Arnold Van Den Berg 271,253 sh (-10.63%)
Diamond Hill Capital 5,357,310 sh (-11.6%)
Joel Greenblatt 100,754 sh (-22.4%)
Ken Fisher 7,713 sh (-30.72%)
Paul Tudor Jones 11,200 sh (-47.42%)
John Hussman 200,000 sh (-60.26%)
Ray Dalio 29,045 sh (-82.44%)
» More
Q3 2013

MDT Guru Trades in Q3 2013

Jim Simons 1,026,700 sh (+2667.39%)
Pioneer Investments 844,648 sh (+136.09%)
Joel Greenblatt 193,635 sh (+92.19%)
Ray Dalio 45,545 sh (+56.81%)
Paul Tudor Jones 14,000 sh (+25%)
Chuck Royce 112,800 sh (+22.74%)
John Buckingham 17,471 sh (+7.6%)
Jeremy Grantham 10,124,082 sh (+4.99%)
John Hussman 205,000 sh (+2.5%)
Manning & Napier Advisors, Inc 361,404 sh (+1.66%)
James Barrow 32,327,133 sh (+0.25%)
Bill Nygren 4,385,000 sh (unchged)
Vanguard Health Care Fund 10,532,800 sh (unchged)
Jean-Marie Eveillard 8,000 sh (unchged)
Chris Davis Sold Out
HOTCHKIS & WILEY 1,749,300 sh (-0.5%)
Diamond Hill Capital 5,313,585 sh (-0.82%)
PRIMECAP Management 31,844,221 sh (-0.89%)
Jeff Auxier 151,720 sh (-1.33%)
Arnold Van Den Berg 265,963 sh (-1.95%)
Bill Frels 4,088,239 sh (-2.27%)
Dodge & Cox 9,591,376 sh (-2.66%)
Ken Fisher 7,387 sh (-4.23%)
John Keeley 34,120 sh (-29.28%)
Scott Black 14,198 sh (-33.36%)
Steven Cohen 16,310 sh (-78.87%)
» More
Q4 2013

MDT Guru Trades in Q4 2013

Scott Black 41,683 sh (+193.58%)
Ray Dalio 132,345 sh (+190.58%)
Paul Tudor Jones 32,191 sh (+129.94%)
Jim Simons 1,512,400 sh (+47.31%)
John Hussman 250,000 sh (+21.95%)
Chuck Royce 133,200 sh (+18.09%)
Steven Cohen 18,543 sh (+13.69%)
John Buckingham 18,507 sh (+5.93%)
Pioneer Investments 877,947 sh (+3.94%)
James Barrow 32,642,450 sh (+0.98%)
Jeremy Grantham 10,186,365 sh (+0.62%)
John Keeley 34,160 sh (+0.12%)
Bill Frels 4,090,802 sh (+0.06%)
Jeff Auxier 151,720 sh (unchged)
Bill Nygren 4,385,000 sh (unchged)
Vanguard Health Care Fund 10,532,800 sh (unchged)
Jean-Marie Eveillard 8,000 sh (unchged)
HOTCHKIS & WILEY 1,740,800 sh (-0.49%)
PRIMECAP Management 31,614,803 sh (-0.72%)
Diamond Hill Capital 5,272,970 sh (-0.76%)
Ken Fisher 7,020 sh (-4.97%)
Dodge & Cox 9,019,976 sh (-5.96%)
Manning & Napier Advisors, Inc 202,619 sh (-43.94%)
Arnold Van Den Berg 133,283 sh (-49.89%)
Joel Greenblatt 90,485 sh (-53.27%)
» More
Q1 2014

MDT Guru Trades in Q1 2014

Arnold Van Den Berg Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDT

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Arnold Van Den Berg 2014-03-31 Sold Out 0.72%$53.6 - $60.84 $ 58.551%0
Arnold Van Den Berg 2013-12-31 Reduce -49.89%0.7%$52.46 - $58.84 $ 58.553%133283
Joel Greenblatt 2013-12-31 Reduce -53.27%0.18%$52.46 - $58.84 $ 58.553%90485
John Hussman 2013-12-31 Add 21.95%0.18%$52.46 - $58.84 $ 58.553%250000
Scott Black 2013-12-31 Add 193.58%0.17%$52.46 - $58.84 $ 58.553%41683
Ray Dalio 2013-12-31 Add 190.58%0.04%$52.46 - $58.84 $ 58.553%132345
Joel Greenblatt 2013-09-30 Add 92.19%0.16%$51.51 - $55.88 $ 58.559%193635
Scott Black 2013-09-30 Reduce -33.36%0.04%$51.51 - $55.88 $ 58.559%14198
Ray Dalio 2013-09-30 Add 56.81%0.01%$51.51 - $55.88 $ 58.559%45545
John Keeley 2013-09-30 Reduce -29.28%0.01%$51.51 - $55.88 $ 58.559%34120
John Hussman 2013-06-30 Reduce -60.26%0.52%$45.61 - $53.51 $ 58.5518%200000
Arnold Van Den Berg 2013-06-30 Reduce -10.63%0.15%$45.61 - $53.51 $ 58.5518%271253
James Barrow 2013-06-30 Add 4.65%0.12%$45.61 - $53.51 $ 58.5518%32245022
Joel Greenblatt 2013-06-30 Reduce -22.4%0.07%$45.61 - $53.51 $ 58.5518%100754
Ray Dalio 2013-06-30 Reduce -82.44%0.06%$45.61 - $53.51 $ 58.5518%29045
John Hussman 2013-03-31 Reduce -69.54%1.25%$41.02 - $47.22 $ 58.5529%503300
Yacktman Focused Fund 2013-03-31 Sold Out 0.26%$41.02 - $47.22 $ 58.5529%0
Yacktman Fund 2013-03-31 Sold Out 0.23%$41.02 - $47.22 $ 58.5529%0
James Barrow 2013-03-31 Add 4.9%0.12%$41.02 - $47.22 $ 58.5529%30813326
Donald Yacktman 2013-03-31 Sold Out 0.1%$41.02 - $47.22 $ 58.5529%0
Ray Dalio 2013-03-31 Reduce -25.25%0.02%$41.02 - $47.22 $ 58.5529%165445
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Medtronic, Inc.

Diamond Hill Capital Comments on Medtronic Inc - Oct 24, 2012

Medical device manufacturer Medtronic, Inc. (MDT) reported results that were in-line with Wall Street analysts' expectations but demonstrated sequential improvement in underlying trends, including sales growth excluding foreign exchange affects. Medtronic's growth prospects benefited from market share gains in the Drug-eluting Stent (DES) business, with a better than expected launch of the Resolute Integrity stent. A focus on the international opportunities, specifically China, should also improve long-term potential.

From Diamond Hill Capital's third quarter Select Fund Commentary.


Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Medtronic, Inc.

Diamond Hill Capital's Top Five Holdings
Over the past quarter Diamond Hill Capital added seven new stocks to its portfolio, bringing the total number of stocks to 152 valued at $10.96 billion. The fund manages five long-only equity strategies, three alternative equity strategies and a fixed income strategy. Read more...
Diamond Hill Capital Update and Top Three
Founded in year 2000, Diamond Hill Capital Management lists assets under management of $10.7 billion, as of April 30, 2013. Independent and publicly owned, Diamond Hill is listed on Nasdaq (DHIL) and included in the Russell 2000 Index. Led by Corporate CEO Ric Dillon, Diamond Hill manages five long-only equity strategies, three alternative equity strategies and a fixed income strategy. Here's an update on Diamond Hill Capital’s top three holdings and how those companies are performing in the first quarter of 2013: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 16.50
MDT's P/E(ttm) is ranked higher than
87% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 26.70 vs. MDT: 16.50 )
MDT' s 10-Year P/E(ttm) Range
Min: 10.14   Max: 43.51
Current: 16.5

10.14
43.51
P/B 3.00
MDT's P/B is ranked higher than
60% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. MDT: 3.00 )
MDT' s 10-Year P/B Range
Min: 2.03   Max: 7.76
Current: 3

2.03
7.76
P/S 3.50
MDT's P/S is ranked lower than
58% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. MDT: 3.50 )
MDT' s 10-Year P/S Range
Min: 1.92   Max: 7.97
Current: 3.5

1.92
7.97
PFCF 13.30
MDT's PFCF is ranked higher than
90% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. MDT: 13.30 )
MDT' s 10-Year PFCF Range
Min: 9.2   Max: 70.14
Current: 13.3

9.2
70.14
EV-to-EBIT 13.50
MDT's EV-to-EBIT is ranked higher than
83% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 20.80 vs. MDT: 13.50 )
MDT' s 10-Year EV-to-EBIT Range
Min: 8.8   Max: 24.4
Current: 13.5

8.8
24.4
PEG 1.50
MDT's PEG is ranked higher than
79% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. MDT: 1.50 )
MDT' s 10-Year PEG Range
Min: 1.06   Max: 19.93
Current: 1.5

1.06
19.93
Shiller P/E 19.00
MDT's Shiller P/E is ranked higher than
87% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 26.95 vs. MDT: 19.00 )
MDT' s 10-Year Shiller P/E Range
Min: 12.18   Max: 59.83
Current: 19

12.18
59.83

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.90
MDT's Dividend Yield is ranked higher than
73% of the 166 Companies
in the Global Medical Devices industry.

( Industry Median: 1.29 vs. MDT: 1.90 )
MDT' s 10-Year Dividend Yield Range
Min: 0.5   Max: 2.93
Current: 1.9

0.5
2.93
Dividend Payout 0.31
MDT's Dividend Payout is ranked higher than
58% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 0.35 vs. MDT: 0.31 )
MDT' s 10-Year Dividend Payout Range
Min: 0.13   Max: 2.04
Current: 0.31

0.13
2.04
Dividend growth (3y) 8.20
MDT's Dividend growth (3y) is ranked higher than
79% of the 67 Companies
in the Global Medical Devices industry.

( Industry Median: 8.20 vs. MDT: 8.20 )
MDT' s 10-Year Dividend growth (3y) Range
Min: 8.2   Max: 28.4
Current: 8.2

8.2
28.4
Yield on cost (5-Year) 2.87
MDT's Yield on cost (5-Year) is ranked higher than
82% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 1.35 vs. MDT: 2.87 )
MDT' s 10-Year Yield on cost (5-Year) Range
Min: 0.76   Max: 4.43
Current: 2.87

0.76
4.43
Share Buyback Rate 2.50
MDT's Share Buyback Rate is ranked higher than
94% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: -1.30 vs. MDT: 2.50 )
MDT' s 10-Year Share Buyback Rate Range
Min: 2.6   Max: -8.5
Current: 2.5

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.20
MDT's Price/Tangible Book is ranked lower than
72% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. MDT: 9.20 )
MDT' s 10-Year Price/Tangible Book Range
Min: 6.27   Max: 44.29
Current: 9.2

6.27
44.29
Price/DCF (Projected) 1.00
MDT's Price/DCF (Projected) is ranked higher than
85% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. MDT: 1.00 )
MDT' s 10-Year Price/DCF (Projected) Range
Min: 0.77   Max: 6.95
Current: 1

0.77
6.95
Price/Median PS Value 1.00
MDT's Price/Median PS Value is ranked higher than
73% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. MDT: 1.00 )
MDT' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 3.34
Current: 1

0.62
3.34
Price/Peter Lynch Fair Value 1.60
MDT's Price/Peter Lynch Fair Value is ranked higher than
76% of the 59 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. MDT: 1.60 )
MDT' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.11   Max: 6.46
Current: 1.6

1.11
6.46
Price/Graham Number 2.60
MDT's Price/Graham Number is ranked higher than
51% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. MDT: 2.60 )
MDT' s 10-Year Price/Graham Number Range
Min: 2.1   Max: 11.15
Current: 2.6

2.1
11.15
Earnings Yield (Greenblatt) 7.40
MDT's Earnings Yield (Greenblatt) is ranked higher than
86% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. MDT: 7.40 )
MDT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.1   Max: 11.3
Current: 7.4

4.1
11.3
Forward Rate of Return (Yacktman) 15.36
MDT's Forward Rate of Return (Yacktman) is ranked higher than
93% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. MDT: 15.36 )
MDT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.3   Max: 23.6
Current: 15.36

3.3
23.6

Business Description

Industry: Medical Devices » Medical Devices
Compare:SYK, SMA, ZMH, STJ, EW » details
Traded in other countries:MDT.Germany
Medtronic, Inc., was incorporated as a Minnesota corporation in 1957. The Company is engaged in providing medical technology- alleviating pain, restoring health, and extending life for people. The Company develops, manufactures, and markets its medical devices in more than 140 countries. Its products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes, and ear, nose, and throat conditions. The Company's operating segments are: Cardiac and Vascular Group; and Restorative Therapies Group. Cardiac and Vascular Group includes Cardiac Rhythm Disease Management (CRDM) and CardioVascular. Restorative Therapies Group includes Spinal, Neuromodulation, Diabetes, and Surgical Technologies. CRDM develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), and information systems for the management of patients with CRDM devices. CardioVascular is composed of the following three businesses: Coronary, Endovascular and Peripheral, and Structural Heart. Its Spinal business develops, manufactures, and markets a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. Its Neuromodulation business develops, manufactures, and markets medical devices for the treatment of chronic pain, movement disorders, psychological disorders, and urological, fecal, and gastroenterological disorders. Its Diabetes business develops, manufactures, and markets advanced, integrated diabetes management solutions that include insulin pump therapy, continuous glucose monitoring systems, and therapy management software. Its Surgical Technologies business develops, manufactures, and markets products and therapies to treat diseases and conditions of the ear, nose, and throat (ENT) and certain neurological disorders. In addition, the business develops, manufactures, and markets image-guided surgery and intra-operative imaging systems that facilitate surgical planning during precision cranial, spinal, sinus, and orthopedic surgeries. Its main customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. Its competitors are St. Jude Medical, Inc., Boston Scientific Corporation, Biotronik, Inc., Sorin Group, Abbott Laboratories and Boston Scientific, GETINGE AB, and Terumo Medical Corporation. The Company's medical devices are subject to regulation by numerous government agencies, including the U.S.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide